GlassScriptPhysician profile
Julia Thomas
NPI 1720633928
$6,377.51
in general payments reported to CMS, 2019-2025
28 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,317 · 2022: $1,408 · 2023: $2,465 · 2024: $693 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,727 · Travel and Lodging: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,727.30 |
| Travel and Lodging | $925.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $1,315.66 | 2023 | Intracept |
| Medtronic, INC. | $744.31 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Nevro Corp. | $577.73 | 2021-2024 | Senza |
| Abbvie INC. | $566.53 | 2021-2022 | |
| Protega Pharmaceutials INC | $469.26 | 2023-2025 | Roxybond |
| Biohaven Pharmaceuticals, INC. | $412.94 | 2021 | |
| Scilex Pharmaceuticals INC. | $370.68 | 2021-2025 | Ztlido |
| Pfizer INC. | $299.60 | 2023-2025 | |
| Amgen INC. | $242.91 | 2022-2023 | Aimovig |
| Biohaven Pharmaceutical Holding Company LTD. | $213.06 | 2022 | |
| Boston Scientific Corporation | $160.85 | 2022-2024 | |
| Collegium Pharmaceutical, INC. | $156.47 | 2021-2023 | Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.68 | 2021-2025 | Relistor |
| Ossur Americas, INC. | $112.03 | 2025 | Unloader One X |
| Averitas Pharma INC. | $98.91 | 2023-2024 | Qutenza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $71.97 | 2025 | Sprint Pns System |
| Lilly USA, LLC | $69.08 | 2021-2023 | Emgality |
| Horizon Therapeutics Plc | $48.33 | 2022 | |
| Supernus Pharmaceuticals, INC. | $48.13 | 2021 | |
| Redhill Biopharma INC. | $47.90 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $40.47 | 2025 | |
| Nalu Medical, INC. | $36.47 | 2022-2023 | Nalu Neurostimulation System |
| Pacira Pharmaceuticals Incorporated | $30.71 | 2023 | Zilretta, Iovera |
| Biodelivery Sciences International, INC. | $26.83 | 2021 | |
| Ibsa Pharma INC. | $22.11 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.36 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.82 | 2022 | |
| Mdd US Operations, LLC | $12.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.